Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • fritzwebSTANNA
    Junior Member
    • Oct 2015
    • 2

    #1

    osteosarcoma survival data set

    Hi all,

    I am a researcher at St. Anna Children's Cancer Research Institute in Vienna, Austria.

    I was wondering if anyone of you would know a publicly available dataset of osteosarcoma survival times (from day of diagnosis or day of first surgery). That would be highly appreciated.
    Also, I am interested in Ewing sarcoma and soft-tissue sarcoma dataset.

    Thank you so much in advance for your help!

    Best regards
    Friedrich Erhart
  • papori
    Senior Member
    • Dec 2010
    • 181

    #2
    Originally posted by fritzwebSTANNA View Post
    Hi all,

    I am a researcher at St. Anna Children's Cancer Research Institute in Vienna, Austria.

    I was wondering if anyone of you would know a publicly available dataset of osteosarcoma survival times (from day of diagnosis or day of first surgery). That would be highly appreciated.
    Also, I am interested in Ewing sarcoma and soft-tissue sarcoma dataset.

    Thank you so much in advance for your help!

    Best regards
    Friedrich Erhart
    Hi Friedrich ,
    Did u try the data from the TCGA?
    i know there is alot of clinical data.
    Cheers
    Last edited by papori; 10-15-2015, 12:58 AM.

    Comment

    • fritzwebSTANNA
      Junior Member
      • Oct 2015
      • 2

      #3
      Yes, I tried that. They have a lot of gene expression datasets for adult sarcomas. What I am looking for, however, are survival data sets for pediatric osteosarcoma, Ewing sarcoma and soft-tissue sarcoma.

      Thank you all for your help! :-)

      Comment

      • GenoMax
        Senior Member
        • Feb 2008
        • 7142

        #4
        You may have to find relevant paper(s) and then contact the authors to get survival data. I am not if you are going to find this information from a public resource.

        Comment

        • freidariviere
          Junior Member
          • Oct 2015
          • 1

          #5
          I think though the answer to your question can come from common sense . . osteosarcoma is an aggressive type of bone cancer and it stands to reason that if a patient is found at an early stage of the disease it is far easier to treat successfully than when it is in an advanced state. But there are no guarantees . . even in the early stages osteosarcoma is aggressive and nasty enough that heavy duty treatments are often required to PREVENT it from advancing. Survival depends on many factors . . age of patient, patients overall health, location of tumors, grade of tumor, and patients response to first line treatment . . not to mention a good amount of 'luck'. People with single tumors who might not survive would include those who are in poor health to begin with, those unable to undergo treatments, those who succumb to the treatment or surgery, those whose age works against them, those who do not survive infections or those who due to other health issues cannot complete or must use reduced treatment options .. and there may be other reasons as well.
          Fitness Subscription Box, Workout Subscription Box, Healthy Subscription Boxes

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
            by SEQadmin2



            CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

            Despite this, “CRISPR helped turn genome editing from a specialized technique into
            ...
            07-31-2026, 11:01 AM
          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 07:41 AM
          0 responses
          6 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 08-03-2026, 10:13 AM
          0 responses
          21 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-31-2026, 02:55 AM
          0 responses
          35 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          25 views
          0 reactions
          Last Post SEQadmin2  
          Working...